Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper.
Young GC, Spracklin DK, James AD, Hvenegaard MG, Scarfe G, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, van Groen B, Romeo AA, Cassidy KC, Da-Violante G, Bister B, Blech S, Lyer R, Schulz SI, Cuyckens F, Moliner P. Young GC, et al. Among authors: cassidy kc. Clin Pharmacol Ther. 2023 Apr;113(4):775-781. doi: 10.1002/cpt.2691. Epub 2022 Sep 2. Clin Pharmacol Ther. 2023. PMID: 35733280
Non-Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece.
Young GC, Spracklin DK, James AD, Hvenegaard MG, Pedersen ML, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, Romeo AA, Cassidy KC, Da-Violante G, Blech S, Schulz SI, Cuyckens F, Nguyen MA, Scarfe G. Young GC, et al. Among authors: cassidy kc. Clin Pharmacol Ther. 2024 May;115(5):931-938. doi: 10.1002/cpt.3121. Epub 2023 Dec 22. Clin Pharmacol Ther. 2024. PMID: 38018358 Review.
Recommendations on the Use of Multiple Labels in Human Mass Balance Studies.
Cuyckens F, Hvenegaard MG, Cassidy KC, Spracklin DK, James AD, Pedersen ML, Scarfe G, Wagner DS, Georgi K, Schulz SI, Schieferstein H, Bjornsdottir I, Romeo AA, Da Violante G, Blech S, Moliner P, Young GC. Cuyckens F, et al. Among authors: cassidy kc. Drug Metab Dispos. 2024 Feb 14;52(3):153-158. doi: 10.1124/dmd.123.001429. Drug Metab Dispos. 2024. PMID: 38216306 Review.
Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.
Perkins EJ, Cramer JW, Farid NA, Gadberry MG, Jackson DA, Mattiuz EL, O'Bannon DD, Weiss HJ, Wheeler WJ, Wood PG, Cassidy KC. Perkins EJ, et al. Among authors: cassidy kc. Drug Metab Dispos. 2003 Nov;31(11):1382-90. doi: 10.1124/dmd.31.11.1382. Drug Metab Dispos. 2003. PMID: 14570771
Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ, Cassidy KC. Zamek-Gliszczynski MJ, et al. Among authors: cassidy kc. Drug Metab Dispos. 2013 Apr;41(4):714-26. doi: 10.1124/dmd.112.048488. Epub 2013 Jan 10. Drug Metab Dispos. 2013. PMID: 23305709 Clinical Trial.
20 results